Please ensure Javascript is enabled for purposes of website accessibility
Home > Products > Antibodies > Research Grade Biosimilars

Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO) (HV493016)

Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)
Price(USD):
Spec:
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Number:
Get quote
  • Overview

  • Images

  • References

  • Datasheet

  • SDS

Overview
Catalog No.HV493016
Description
Tepoditamab (HV493016) is a research-grade recombinant antibody targeting CD371. Produced in mammalian cells with native-like glycosylation.
Highlights
  • Research Grade — For PK/PD studies, assay development, and ADA research.
  • Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivityHuman
ApplicationsELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host speciesHuman
IsotypeIgG1-kappa
Expression system Mammalian cells
Clonality Monoclonal
Target CLEC12A, DCAL2, Dendritic cell-associated lectin 2, CLL-1, Myeloid inhibitory C-type lectin-like receptor, C-type lectin domain family 12 member A, CLL1, DCAL-2, C-type lectin-like molecule 1, MICL, CD371, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain
Endotoxin level < 10 EU/mg
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Accession Q5QGZ9 & P07766
Form Liquid
Storage buffer 0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Stability and Storage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate NamesBispecific, MCLA-117, PB9122, 2044679-53-8
BackgroundTepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research.
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
Images
  • Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)

    SEC-HPLC

    SEC-HPLC detection for Research Grade Tepoditamab.

  • Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)

    Bioactivity

    Detects CD371/CLEC12A in indirect ELISAs.

  • Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Tepoditamab.

  • Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)

    Flow cytometry

    Flow-cytometry APC using anti-human CD371 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an APC anti-human CD371 monoclonal antibody (Catalog HV493016) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

  • Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)

    Flow cytometry

    Flow-cytometry PE using anti-human CD371 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an PE anti-human CD371 monoclonal antibody (Catalog HV493016) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

  • Anti-Human CD371/CLEC12A & CD3 epsilon Bispecific Reference Antibody (Tepoditamab, RUO)

    Flow cytometry

    Flow-cytometry FITC using anti-human CD371 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an FITC anti-human CD371 monoclonal antibody (Catalog HV493016) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

References
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommendation

Contact us for custom quotes, bulk requests and any other issues.

Mail: [email protected]

Distributor list